NCT02728531View on ClinicalTrials.gov

Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 18, 2016

Primary Completion Date

January 16, 2019

Study Completion Date

August 16, 2023

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

Bendamustine

DRUG

Rituximab

DRUG

Cytarabine

DRUG

Pegfilgrastim

PROCEDURE

Leukapheresis

DRUG

Filgrastim

PROCEDURE

Autologous stem cell transplant

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors

lead

Washington University School of Medicine

OTHER

NCT02728531 - Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter